Key points

• Most often affects women age 60 to 70
• Usually idiopathic and related to vitreomacular traction (VMT) during posterior vitreous detachment
• Can also occur with high myopia or blunt trauma
• Bilateral involvement risk is clinically relevant (about 10% to 30% reported depending on cohort/setting)

Typical symptoms

• Blurred central vision in one eye
• Metamorphopsia (straight lines look wavy)
• Central scotoma
• Early/impending stages may be minimally symptomatic

Diagnosis

• OCT is the key test for confirmation and staging
• Fundus exam may show a round red foveal lesion with a cuff/halo
• Watzke-Allen slit-beam test may show a perceived break in the beam over a true full-thickness hole
• Differentiate from:
  • Lamellar macular hole
  • Macular pseudohole from epiretinal membrane
  • Chronic CME-related cystic changes
  • Solar retinopathy

Staging

• Stage 1: impending hole
• Stage 2: small full-thickness hole
• Stage 3: full-thickness hole, no complete PVD
• Stage 4: full-thickness hole with complete PVD

• Hole size (small, medium, large)
• Presence/absence of VMT
• Etiology (primary vs secondary)

Management

• Stage 1: often observation (many resolve spontaneously)
• Symptomatic full-thickness holes (especially stage 2+): pars plana vitrectomy with ILM peel and gas tamponade is standard of care
• Better outcomes when treated earlier, especially within about 6 months
• Post-op face-down positioning may be used (shorter protocols common with modern techniques)
• Ocriplasmin may be considered in selected early small VMT-related cases, but use is limited by variable efficacy and side effects
• Cataract progression after vitrectomy in phakic patients is very common

Prognosis

• Anatomical closure rates are high after surgery
• Vision often improves over months
• Smaller holes and shorter duration generally have better visual outcomes
• Some full-thickness holes can close spontaneously

Example images

Fundus stages of macular hole:

OCT appearance of macular hole:

• A quick PubMed search limited to the last 2 years for systematic reviews/meta-analyses on “macular hole treatment” returned no hits, so no immediate high-level contradiction signal was identified from that narrow filter.

• Kanski's Clinical Ophthalmology: A Systematic Approach, 10th ed, p. 626-629
• The Wills Eye Manual, p. 866-870

Macular Hole (15-mark answer)

Definition

Epidemiology

• Common in older adults, especially 60 to 70 years
• Female preponderance
• Usually unilateral at presentation, but fellow-eye risk exists (about 10% or more over time)

Etiology and Pathogenesis

1. Idiopathic (most common)
   Related to age-related vitreous changes and anomalous posterior vitreous detachment.
2. Vitreomacular traction (VMT)
   Persistent vitreofoveal adhesion causes anteroposterior and tangential traction, leading to foveal dehiscence.
3. Secondary causes
   • High myopia
   • Blunt ocular trauma
   • Less commonly cystoid macular edema-associated tractional changes

Classification

A. Gass Clinical Staging

• Stage 1: Impending hole (yellow spot/ring at fovea)
• Stage 2: Small full-thickness macular hole
• Stage 3: Full-thickness hole with cuff of subretinal fluid, without complete PVD
• Stage 4: Full-thickness hole with complete PVD

B. OCT-Based Classification (current practical approach)

• Based on:
  • Hole size (small, medium, large)
  • Presence/absence of vitreomacular traction
  • Etiology (primary/secondary)

Clinical Features

Symptoms

• Painless diminution of central vision
• Metamorphopsia
• Central scotoma
• Reading difficulty
• Early stages may be minimally symptomatic

Signs

• Round red foveal lesion
• Gray cuff/halo (subretinal fluid) around full-thickness hole
• Possible operculum
• Loss of normal foveal contour in VMT stages

Investigations

1. Optical Coherence Tomography (OCT)
   Gold standard for diagnosis, staging, and follow-up.
2. Amsler grid
   Detects central distortion.
3. Watzke-Allen test
   Thinning/break in slit beam perception suggests true full-thickness hole.
4. Fundus biomicroscopy
   For morphology and associated vitreoretinal interface abnormalities.
5. FA/FAF (selected cases)
   Usually not required when OCT is diagnostic.

Differential Diagnosis

• Lamellar macular hole
• Macular pseudohole (epiretinal membrane)
• Chronic CME with central cystic change
• Solar retinopathy
• Other foveal lesions mimicking a hole

Management

1. Observation

• Stage 1 holes are often observed because spontaneous resolution can occur.
• Small spontaneous closure can also occur in some full-thickness holes.

2. Pharmacologic vitreolysis

• Ocriplasmin in selected VMT/small early holes
• Limited use due to variable efficacy and adverse effects

3. Surgical treatment (standard for symptomatic full-thickness holes)

• Pars plana vitrectomy + ILM peeling + gas tamponade
• Relieve traction, promote hole closure
• Better outcomes when operated early (preferably within ~6 months of onset)
• Postoperative prone positioning may be advised for selected duration

Prognosis

• High anatomical closure rates after surgery
• Visual recovery occurs over months
• Better visual outcomes with:
  • Smaller hole size
  • Shorter symptom duration
  • Earlier surgery
• Cataract progression in phakic eyes after vitrectomy is common

Complications

• Persistent/recurrent hole
• Cataract progression
• Retinal detachment (uncommon but important)
• Other vitrectomy-related complications

Follow-up

• Monitor with serial OCT
• Counsel regarding symptoms of retinal detachment
• Periodic fellow-eye assessment due to bilateral risk

Short conclusion

CMV Retinitis (15-mark answer)

Definition

Etiology and Risk Factors

• Causative agent: Human cytomegalovirus (HHV-5)
• Major risk groups:
  • HIV with very low CD4 count (especially <50 cells/µL)
  • Solid organ/hematopoietic stem cell transplant
  • Prolonged corticosteroids, chemotherapy, biologics, immunosuppressants
  • Hematologic malignancy, congenital immunodeficiency

Pathogenesis

• CMV reactivation occurs in profound immunosuppression
• Hematogenous spread to retina causes full-thickness retinal necrosis
• Associated occlusive vasculitis and hemorrhage
• Lesions spread centrifugally along vessels if untreated
• Healed lesions become atrophic scars, predisposing to retinal breaks and detachment

Clinical Features

Symptoms

• Floaters
• Blurred vision
• Scotoma
• Photopsia
• Painless progressive visual loss
  (Early peripheral disease may be asymptomatic)

Signs (Fundus)

• Yellow-white granular retinal necrosis with retinal hemorrhages
  classic “pizza pie” or “cottage cheese with ketchup” appearance
• Perivascular whitening/sheathing
• Minimal anterior chamber/vitreous inflammation compared with lesion extent
• May be unilateral initially, with risk of fellow-eye involvement if untreated

Clinical Patterns

1. Fulminant/edematous form
   Dense hemorrhagic necrotizing lesions, often posterior pole
2. Indolent/granular form
   Peripheral granular lesions with slower progression
3. Frosted branch angiitis-like vasculitis (less common)

Diagnosis

1. Dilated fundus examination (cornerstone)
2. Wide-field fundus photography for documentation
3. OCT for macular involvement/complications
4. Aqueous/vitreous PCR (CMV DNA) when diagnosis is uncertain or atypical
5. HIV testing/CD4 count and systemic immunologic workup where relevant

Differential Diagnosis

• Acute retinal necrosis (HSV/VZV)
• Progressive outer retinal necrosis
• Toxoplasma retinochoroiditis
• Syphilitic retinitis
• Candida endophthalmitis
• Intraocular lymphoma

Treatment

1) Anti-CMV induction therapy

• Valganciclovir (oral) commonly used if sight-threatening disease is absent
• IV ganciclovir for severe/bilateral/systemic disease
• Foscarnet (alternative or resistant/intolerant cases)
• Cidofovir less favored due to toxicity profile

2) Local therapy for sight-threatening lesions

• Intravitreal ganciclovir or foscarnet, often combined with systemic therapy for rapid local control

3) Maintenance and immune restoration

• Continue maintenance therapy until immune recovery (in HIV, sustained CD4 improvement on ART)
• Start/optimize ART in HIV patients (timing individualized)
• Coordinate with physician/infectious disease specialist

Monitoring and Follow-up

• Frequent retinal exams during induction (often weekly initially)
• Watch for progression at lesion borders, new lesions, fellow-eye disease
• Hematologic and renal monitoring for drug toxicity
• Long-term follow-up for structural sequelae

Complications

• Rhegmatogenous retinal detachment (major cause of severe visual loss)
• Optic atrophy
• Macular scarring/edema
• Immune recovery uveitis after ART initiation
• Drug adverse effects:
  • Ganciclovir/valganciclovir: neutropenia, thrombocytopenia
  • Foscarnet: nephrotoxicity, electrolyte disturbances
  • Cidofovir: nephrotoxicity, uveitis/hypotony

Prognosis

• Visual outcome depends on:
  • Lesion location (macula/optic nerve involvement worse)
  • Speed of diagnosis and treatment
  • Degree of immune reconstitution
• Prognosis has improved markedly in the ART era, but relapse and late complications remain significant.

Prevention

• Early HIV diagnosis and effective ART
• In transplant and high-risk patients: virologic monitoring and pre-emptive CMV strategies
• Patient education to report new floaters, field defects, or blurred vision immediately

Short conclusion

Pneumatic Retinopexy (15-mark answer)

Definition

Principle

• Gas bubble rises and tamponades superior retinal break(s)
• Subretinal fluid is gradually absorbed by RPE pump
• Laser photocoagulation or cryopexy seals the break permanently
• Strict postoperative head positioning is essential to keep bubble apposed to break

Indications (ideal case selection)

• Primary RRD with:
  • Single break or a small group of breaks within 1 clock hour
  • Break(s) in superior retina (approximately 8 to 4 o'clock)
  • Clear enough media for retinal visualization
  • Patient able to maintain required head posture and follow-up
• Phakic eyes often have better single-procedure success than pseudophakic eyes

Contraindications / Poor candidates

• Inferior retinal breaks
• Large/multiple widely separated tears
• Significant proliferative vitreoretinopathy (PVR C or more)
• Advanced giant retinal tear/dialysis (except selected expert settings)
• Marked vitreous hemorrhage or media opacity
• Inability to posture, travel constraints, or poor compliance
• Need for air travel or nitrous oxide anesthesia while gas persists

Preoperative Evaluation

1. Detailed dilated fundus exam with scleral indentation (both eyes)
2. Identify all breaks and assess PVR
3. Macula-on vs macula-off status documentation
4. Baseline visual acuity and IOP
5. Counsel regarding positioning, follow-up urgency, and red-flag symptoms

Procedure (outline)

1. Topical/local anesthesia and asepsis
2. Paracentesis may be done in selected cases to control IOP
3. Intravitreal injection of expansile gas (commonly SF6 or C3F8; nonexpansile concentration as per protocol)
4. Immediate positioning so bubble occludes causative break
5. Retinopexy:
   • Laser photocoagulation once retina apposes (often within 24 to 48 h), or
   • Cryotherapy at/around break depending on visualization and surgeon preference
6. Serial re-examination to confirm reattachment and detect missed/new breaks

Postoperative Instructions

• Strict head posture for several days as advised
• No air travel, high altitude exposure, or nitrous oxide anesthesia until gas resolves
• Report pain, sudden vision drop, new floaters/flashes immediately
• Frequent early follow-up (often day 1, then within days to week)

Advantages

• Office-based, less invasive
• Short procedure time, lower cost
• Faster recovery and less conjunctival scarring
• Less refractive change and less cataract progression compared with vitrectomy in many cases
• Can preserve future options (scleral buckle/PPV if needed)

Limitations

• Highly dependent on case selection and compliance with posture
• Lower single-procedure success than PPV in some case mixes
• Missed or new retinal breaks can cause failure
• May require secondary surgery

Complications

• Persistent/recurrent retinal detachment
• New or missed retinal breaks
• Elevated IOP, pupillary block (rare)
• Gas migration (rare)
• Vitreous hemorrhage
• Choroidal detachment (uncommon)
• Epiretinal membrane, PVR progression
• Endophthalmitis (very rare)
• Subretinal gas (rare, technique-related)

Outcomes

• Good anatomical and visual outcomes in properly selected superior-break RRD
• Best results in:
  • Phakic eyes
  • Single superior tear
  • Minimal PVR
  • Good adherence to positioning
• Failure usually managed with repeat pneumatic, scleral buckle, or pars plana vitrectomy

Comparison with Other Procedures

• Vs scleral buckle: less invasive, faster recovery, but narrower indications
• Vs PPV: office-based and lens-sparing advantages, but PPV may have higher primary success in complex/pseudophakic/multiple-break detachments

Short conclusion

Intravitreal Implants (15-mark answer)

Definition

Rationale

• Blood-retinal barrier limits systemic drug penetration
• Repeated bolus injections have fluctuating drug levels
• Implants provide longer, steadier intraocular concentration
• Useful in chronic, recurrent retinal disorders

Classification

1) By biodegradability

1. Biodegradable implants
   • Break down over time
   • Usually steroid based
2. Non-biodegradable implants
   • Long-acting reservoir systems
   • May require surgical placement/removal in some designs

2) By drug class

• Corticosteroid implants
• Antiviral implants (historical/selected contexts)
• Anti-VEGF sustained-delivery systems (newer)
• Experimental: immunomodulatory/gene-based long-duration platforms

Commonly used intravitreal implants

A. Dexamethasone biodegradable implant (Ozurdex, 0.7 mg)

• Indications:
  • Diabetic macular edema (selected cases)
  • Macular edema due to retinal vein occlusion
  • Noninfectious posterior uveitis
• Duration: approximately 3 to 6 months (variable)
• Delivered via office-based injector

B. Fluocinolone acetonide implants

1. Iluvien/Yutiq type micro-implant (injectable, very low dose release)
   • Long duration (up to about 3 years in approved settings)
   • Used in chronic DME (selected patients) and noninfectious uveitis (product/region dependent)
2. Retisert type surgical implant
   • Sutured implant for chronic noninfectious posterior uveitis
   • High local steroid effect but higher ocular side-effect burden

C. Ganciclovir implant (historical)

• Used in CMV retinitis before modern systemic/ART era strategies
• Largely replaced by current systemic + intravitreal pharmacotherapy protocols

D. Ranibizumab port delivery system (PDS) (where available)

• Refillable sustained-release anti-VEGF reservoir for neovascular AMD
• Reduces injection frequency but requires surgical implantation and monitoring

Indications (exam-friendly)

• Chronic/refractory diabetic macular edema
• Macular edema due to RVO
• Noninfectious intermediate/posterior/panuveitis
• Selected neovascular AMD (sustained anti-VEGF systems)
• Rarely/older indication: CMV retinitis (ganciclovir implant)

Contraindications

• Active ocular/periocular infection
• Active infectious uveitis (for steroid implants)
• Advanced uncontrolled glaucoma
• Significant media opacity precluding follow-up (relative)
• Hypersensitivity to implant components

Technique (general outline)

1. Informed consent and indication confirmation
2. Aseptic intravitreal procedure in OT/procedure room
3. Pars plana entry with preloaded injector (for injectable implants)
4. Check optic nerve perfusion/IOP and implant position
5. Post-procedure monitoring and scheduled follow-up

Advantages

• Sustained drug delivery and reduced treatment burden
• Better adherence in chronic disease
• Lower systemic exposure than systemic therapy
• Useful when frequent visits/injections are difficult

Disadvantages

• Procedure-related risks
• Steroid-response glaucoma and cataract
• Cost and availability limitations
• Some systems require surgery/refill

Complications

1. Common/important
   • Raised IOP, steroid-induced glaucoma
   • Cataract progression (especially with steroid implants)
2. Procedure-related
   • Endophthalmitis
   • Vitreous hemorrhage
   • Retinal tear/detachment (rare)
   • Hypotony (rare)
3. Implant-specific
   • Implant migration (risk in aphakia or posterior capsular defects for dexamethasone implant)
   • Device erosion/exposure or conjunctival complications (surgical implants)
   • Need for re-implantation/refill as effect wanes

Follow-up

• Monitor visual acuity, OCT, IOP, lens status
• Watch for infection or inflammation
• Re-treatment planning based on anatomical and functional response
• In steroid implants, regular glaucoma surveillance is mandatory

Comparison with repeated intravitreal injections

• Implants: fewer procedures, steadier drug levels, but device-related risks and steroid effects
• Monthly/PRN injections: flexible and titratable, but high visit burden and adherence issues

Short conclusion